News

February 19, 2008 – Clinicians implanted the BioMatrix drug-eluting stent system into the first European patients in a live broadcast during the Joint Interventional Meeting (JIM), held in Rome,...

February 18, 2008 – OrbusNeich’s Genous Bio-engineered R stent is feasible and safe for use in acute myocardial infarction (AMI) patients, according to a paper published in the American Heart...

February 1, 2008 - Stentys' bifurcated stent was successfully implanted recently into a 49-year-old male patient at the ThoraxCenter, Erasmus Medical Center, Rotterdam, the Netherlands, marking...

January 24, 2008 – “Unadjusted mortality…was significantly lower for drug-eluting stents than bare-metal stents in unapproved indications,” noted Donald S.

January 22, 2008 - A new stent with a nanothin surface application known as Polyzene-F shows promise in opening and healing blocked heart arteries reportedly without the potential risks of...

January 10, 2008 - Patients who received OrbusNeich’s Genous Bio-engineered R Stent had significantly fewer major cardiac adverse events (MACE) than patients who received FDA-cleared drug-eluting...

January 8, 2008 - Compared with paclitaxel-eluting stents (PES), sirolimus-eluting stents (SES) appear to decrease the risk of in-stent late luminal loss in diabetics with coronary artery disease...

December 27, 2007 - Several new studies on genetics and stem cell research, along with studies that continue to debate the use of stents to clear coronary artery blockages are among the top...

November 5, 2007 - A pooled analysis of the E-SIRIUS and C-SIRIUS trials, called New SIRIUS, found that the CYPHER sirolimus-eluting coronary stent continued to provide clinical benefits with...

November 4, 2007 – Drug-eluting stents to open blocked coronary arteries caused no more risks for death or heart attack than bare metal stents, according to a late-breaking outcomes trial...

October 23, 2007 – After 12 months of the SPIRIT III trial, there were significantly fewer major adverse cardiac events (MACE) such as heart attacks, deaths from cardiac causes or repeat...

October 18, 2007 - Abbott announced that trial results for ABSORB, the world’s first clinical trial evaluating the safety and performance of a fully bioabsorbable drug eluting stent platform for...

August 13, 2007 – A study published in the Journal of the American College of Cardiology showed that when AngioJet thrombectomy is used to remove large thrombus before placement of a drug-eluting...

August 8, 2007 - A U.S. District Court judge enforced a settlement this week between Abbott Laboratories Inc. and Israeli company Medinol Ltd. to removed an entanglement for a key drug-eludting...

June 1, 2007 — Abbott announced it has completed its application to the U.S. Food and Drug Administration (FDA) to seek market approval for its XIENCE V Everolimus Eluting Coronary Stent System to...